Growth Hormone Quiz: The Signal That Drives Development

Growth hormone is a 191-amino acid peptide hormone secreted in pulses from somatotroph cells of the anterior pituitary. It binds receptors on target tissues including the liver, muscle, bone, and adipose tissue, activating JAK-STAT signaling. Growth hormone promotes lipolysis, protein anabolism, and glucose sparing. Its most significant growth-promoting effects on skeletal elongation and tissue building are mediated largely through stimulation of IGF-1 production in the liver and locally in target tissues.

Growth hormone secretion is tightly regulated by a dual hypothalamic control system. Growth hormone-releasing hormone is synthesized in the arcuate nucleus and stimulates somatotroph cells to produce and release growth hormone. Somatostatin, produced in the periventricular nucleus, acts as a physiological brake suppressing growth hormone release. The interplay between these opposing signals, along with feedback from circulating IGF-1, generates the characteristic pulsatile secretion pattern of growth hormone throughout the day.

Growth hormone has direct effects on multiple tissues. It stimulates lipolysis in adipose cells through hormone-sensitive lipase activation. It antagonizes insulin signaling in muscle and fat, raising blood glucose levels. It promotes protein synthesis by enhancing amino acid transport. Thyroid hormone synthesis is regulated by TSH from the anterior pituitary and TRH from the hypothalamus; growth hormone does not directly regulate thyroid hormone production, making that option incorrect.

IGF-1 is a 70-amino acid peptide with structural similarity to insulin, synthesized predominantly by hepatocytes in response to growth hormone signaling through JAK2-STAT5. Circulating IGF-1 acts systemically as an endocrine hormone, while locally produced IGF-1 acts in autocrine and paracrine fashions. IGF-1 binds its receptor tyrosine kinase to activate PI3K-AKT-mTOR and RAS-MAPK pathways, stimulating chondrocyte proliferation and hypertrophy in growth plates, myoblast differentiation, and survival signaling across many tissues.

Longitudinal bone growth occurs through endochondral ossification at the epiphyseal growth plate. Growth hormone acts on resting zone chondrocytes to stimulate their entry into active proliferation. IGF-1, both delivered systemically from the liver and produced locally within the growth plate, promotes chondrocyte hypertrophy, matrix production, and mineralization in the proliferative and hypertrophic zones. This cartilage expansion is progressively replaced by bone, pushing the epiphysis away from the diaphysis and elongating the bone.

Growth hormone deficiency causes proportionate short stature, reduced muscle mass, increased adiposity, and delayed skeletal maturation as measured by bone age on radiographic imaging. Recombinant human growth hormone, produced using recombinant DNA technology, effectively replaces the deficient hormone when administered subcutaneously. Treatment stimulates hepatic IGF-1 production, restores growth plate chondrocyte activity, and substantially improves final adult height when initiated early enough in childhood before growth plate fusion.

Negative feedback regulation of the growth hormone axis involves IGF-1 acting at multiple levels. Elevated circulating IGF-1 stimulates somatostatin secretion from the hypothalamus and suppresses growth hormone-releasing hormone, reducing the drive for growth hormone release. IGF-1 also acts directly on anterior pituitary somatotrophs to reduce their sensitivity to growth hormone-releasing hormone and decrease growth hormone secretion. This dual negative feedback maintains growth hormone and IGF-1 within physiological ranges and prevents pathological overgrowth.

Acromegaly results from chronic excess growth hormone secretion in adults, most commonly from a benign pituitary somatotroph adenoma. Because epiphyseal growth plates have fused, excess IGF-1 cannot drive linear bone elongation. Instead, growth hormone-driven IGF-1 excess causes soft tissue proliferation, acral overgrowth of hands, feet, and facial features, visceral organ enlargement, insulin resistance, hypertension, and increased cancer risk. If the same excess occurs before growth plate fusion in children, the condition is called gigantism.

Growth hormone secretion peaks during slow-wave sleep, making sleep quality important for normal growth, particularly in children. Malnutrition uncouples the growth hormone-IGF-1 axis by reducing hepatic IGF-1 despite normal or elevated growth hormone, explaining growth faltering in undernourished children. Exercise is a potent physiological stimulus for growth hormone release. IGF-1 levels are far from constant, peaking in late puberty, declining in adulthood, and falling significantly with aging and in malnutrition, making the fourth option incorrect.

IGF-1 receptor activation stimulates PI3K to generate the second messenger PIP3 at the plasma membrane. PIP3 recruits PDK1 and AKT, and PDK1-mediated AKT phosphorylation activates this pro-survival kinase. Activated AKT phosphorylates BAD, preventing it from triggering cytochrome c release from mitochondria. AKT also phosphorylates FOXO transcription factors, retaining them in the cytoplasm and preventing transcription of pro-apoptotic genes. This AKT-driven survival signaling integrates with mTOR activation to coordinate growth and survival responses to IGF-1.

Sex steroids play a critical permissive and amplifying role in the adolescent growth spurt. Estrogen and testosterone increase growth hormone pulse amplitude and frequency by acting at the hypothalamic and pituitary levels. They also enhance growth plate sensitivity to IGF-1 and locally stimulate periosteal bone apposition. However, prolonged estrogen exposure ultimately accelerates epiphyseal growth plate fusion, limiting the duration of rapid growth and determining final adult height, making the relationship between sex steroids and growth both stimulatory and eventually limiting.

Six major IGF-binding proteins circulate in blood and regulate IGF-1 availability. The predominant complex contains IGFBP-3 with an acid-labile subunit, which greatly extends IGF-1 half-life from minutes to hours. These binding proteins modulate the free IGF-1 fraction available to bind receptors, create tissue-specific reservoirs of IGF-1, and can be cleaved by local proteases to release active IGF-1 at sites of injury or growth. Some IGFBPs also have intrinsic biological activities in apoptosis and cell adhesion independent of IGF-1 binding.

The somatopause, the age-related decline in growth hormone secretion beginning in the third to fourth decade of life, results in progressively lower circulating IGF-1. This contributes to age-related sarcopenia through reduced protein anabolic signaling, increased visceral fat accumulation, declining bone mineral density, reduced physical performance, and impaired tissue repair capacity. The biological consequences of somatopause overlap with other aging processes, making it a target of interest in longevity research, though growth hormone replacement in healthy older adults remains controversial.

Growth hormone promotes lipolysis and protein anabolism. IGF-1 stimulates mTOR-driven protein synthesis in muscle and other tissues. Both hormones influence immune function through receptors on immune cells. Growth hormone does not bind insulin receptors. Acromegaly causes insulin resistance and hyperglycemia rather than hypoglycemia, because growth hormone antagonizes insulin action by reducing glucose uptake in muscle and fat and increasing hepatic glucose output.

The combination of proportionate short stature, delayed bone age, low circulating IGF-1, and a subnormal peak growth hormone response to stimulation testing meets diagnostic criteria for growth hormone deficiency. Recombinant human growth hormone administered by daily subcutaneous injection is the standard treatment. It stimulates hepatic IGF-1 production, restores chondrocyte proliferation and hypertrophy at the growth plate, and has been demonstrated in randomized clinical trials to significantly improve final adult height when treatment is initiated while growth plates remain open.